Drug safety assessment in clinical trials: methodological challenges and opportunities
Open Access
- 20 August 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 13 (1), 138
- https://doi.org/10.1186/1745-6215-13-138
Abstract
Randomized controlled trials are the principal means of establishing the efficacy of drugs. However pre-marketing trials are limited in size and duration and exclude high-risk populations. They have limited statistical power to detect rare but potentially serious adverse events in real-world patients. We summarize the principal methodological challenges in the reporting, analysis and interpretation of safety data in clinical trials using recent examples from systematic reviews. These challenges include the lack of an evidentiary gold standard, the limited statistical power of randomized controlled trials and resulting type 2 error, the lack of adequate ascertainment of adverse events and limited generalizability of trials that exclude high risk patients. We discuss potential solutions to these challenges. Evaluation of drug safety requires careful examination of data from heterogeneous sources. Meta-analyses of drug safety should include appropriate statistical methods and assess the optimal information size to avoid type 2 errors. They should evaluate outcome reporting biases and missing data to ensure reliable and accurate interpretation of findings. Regulatory and academic partnerships should be fostered to provide an independent and transparent evaluation of drug safety.Keywords
This publication has 48 references indexed in Scilit:
- Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ, 2011
- The ClinicalTrials.gov Results Database — Update and Key IssuesThe New England Journal of Medicine, 2011
- Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic reviewBMJ, 2010
- Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and updateCurrent Opinion in Pulmonary Medicine, 2010
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseThe New England Journal of Medicine, 2008
- Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary DiseaseJAMA, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004